Bharat Biotech’s Chairman and Managing Director, Dr. Krishna Ella said that they are awaiting approval from the Drug Controller General of India (DCGI) for a C-19 vaccine for children. He said their vaccines for children The results were “extremely good”.
“We have done clinical trials for gender and age and the results are very good. The security profile is very good, security is of paramount importance.
The SEC (Subject Expert Committee) has approved it and now we are waiting for approval from DCGI. Referring to the nasal vaccine, he said it is going to be “a weapon to control C-19 transmission”.
“We have almost completed Phase II trials for the nasal vaccine and have shown good results. This vaccine will help in controlling the transmission of C-19 infection.
He said that many companies are trying to come up with nasal vaccines and one has to understand the immunology part first.
Given that C-19 vaccines help prevent hospital visits, not necessarily the disease He said that even vaccinated people are advised to wear masks so that the infection does not spread.
“We want everyone to wear a mask, but if it (nasal vaccine) comes, it will stop transmission. So it will work on the whole transition. The virus will not infect and when the virus is not infected, there is no transmission to others.
We are working hard. Referring to India’s historic achievement of delivering over 100 crore C-19 vaccine doses, Dr. Ella said that India has “done an amazing job” in achieving the milestone.
“We appreciate the commitment of the government and health workers are also the most important. I salute the citizens of this country as they are actively working in the interest of science. This was due to the collective efforts of citizens from the government.
According to the agency, Bharat Biotech, a Hyderabad-based company that makes vaccines, released the Phase-2 and Phase-3 trial data related to the vaccination of children between the ages of 2 and 18 this month.
It was handed over to the Central Drugs Standard Control Organization (CDSCO) in the beginning itself. The company handed over these data to CDSCO for verification and then emergency approval.
